Search results
Background and objective: Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.
24 paź 2024 · Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world coho ... of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults . Management of vulnerable patients hospitalized for COVID-19 ...
16 maj 2020 · The median age of study patients was 65 years (IQR 56–71); sex distribution was 89 (56%) men versus 69 (44%) women in the remdesivir group and 51 (65%) versus 27 (35%) in the placebo group (table 1). The most common comorbidity was hypertension, followed by diabetes and coronary heart disease.
21 lut 2023 · We conducted a systematic review and individual patient data meta-analysis to evaluate the benefits and harms of remdesivir compared with placebo or usual care in patients treated in hospital for COVID-19 and whether treatment effects differed between subgroups of patients.
2 maj 2022 · Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
15 gru 2021 · Using a data set from a large, geographically diverse multi-hospital health system in the United States, we quantified the effectiveness of remdesivir in the treatment of hospitalized patients with COVID-19, with a focus on patients with different disease severity at time of treatment initiation.
30 lip 2020 · Recommendation 1 We suggest remdesivir rather than no remdesivir in patients with severe covid-19 Usual supportive care Remdesivir or 100 mg intravenously daily for 5-10 days No remdesivir Strong Weak Weak Strong Resource limited settings. Evidence profile. Individual considerations.
